Protein A/G Sepharose® (ab193262)
Overview
-
Product name
Protein A/G Sepharose® -
Product overview
High binding capacity Protein A/G Sepharose (>20 mg IgG/mL). Minimal leaching of ligand. Suitable for column or batch purification of IgG.
Contents:
Supplied as a 50% slurry in 20% Ethanol; >1.5 mg Protein A/G per mL Sepharose® beads.
Features:
Binding capacity greater than 20 mg of wet gel; high flow rate; low falling off of rProtein A/G; pH stability 2-10.
These beads are for use in column purification. If used in batch purification, we recommend not exceeding 150 x g when centrifuging.
Store beads at 4°C.
The beads may be damaged above 40°C.
DO NOT FREEZE.
Wash beads 3 times with 3x bead volume of desired buffer before use.
Applications:
Purification of monoclonal and polyclonal antibodies.
Sepharose is a registered trademark of GE Healthcare
-
Notes
This product is manufactured by BioVision, an Abcam company and was previously called 6503 Protein A/G Sepharose. 6503-1 is the same size as the 1 ml size of ab193262.
Protein A/G Sepharose® is prepared by covalently coupling recombinant Protein A/G (contains five Ig-binding regions of protein A and three Ig-binding regions of protein G) to 6% cross-linked Sepharose® beads. The coupling was optimized to give a high binding capacity for IgG. The capacity of IgG binding could be greater than 20 mg of rabbit IgG per ml of wet gel.
-
Tested applications
Suitable for: Purificationmore details
Properties
-
Storage instructions
Store at +4°C. Please refer to protocols. -
Components 1 ml 5 ml 25 ml 100 ml Protein A/G Sepharose® 1 x 1ml 1 x 5ml 1 x 25ml 1 x 100ml -
Research areas
Associated products
-
Related Products
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab193262 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
| Application | Abreviews | Notes |
|---|---|---|
| Purification |
Use at an assay dependent concentration.
Purification of monoclonal and polyclonal antibodies. |
| Notes |
|---|
|
Purification
Use at an assay dependent concentration. Purification of monoclonal and polyclonal antibodies. |
Datasheets and documents
-
SDS download
-
Datasheet download
References (8)
ab193262 has been referenced in 8 publications.
- Zhao Z et al. Dexmedetomidine inhibits the PSD95-NMDA receptor interaction to promote functional recovery following traumatic brain injury. Exp Ther Med 21:4 (2021). PubMed: 33235613
- Tao Z et al. Sirt1 coordinates with ERa to regulate autophagy and adiposity. Cell Death Discov 7:53 (2021). PubMed: 33723227
- Kovács RÁ et al. Identification of Neuronal Pentraxins as Synaptic Binding Partners of C1q and the Involvement of NP1 in Synaptic Pruning in Adult Mice. Front Immunol 11:599771 (2020). PubMed: 33628204
- Wei M et al. NDRG2 regulates adherens junction integrity to restrict colitis and tumourigenesis. EBioMedicine 61:103068 (2020). PubMed: 33099085
- Le-Bel G et al. Analysis of the proteasome activity and the turnover of the serotonin receptor 2B (HTR2B) in human uveal melanoma. Exp Eye Res 184:72-77 (2019). PubMed: 31002821
- Song H et al. METTL3 and ALKBH5 oppositely regulate m6A modification of TFEB mRNA, which dictates the fate of hypoxia/reoxygenation-treated cardiomyocytes. Autophagy 15:1419-1437 (2019). PubMed: 30870073
- Gao Y et al. Effects of farnesoid-X-receptor SUMOylation mutation on myocardial ischemia/reperfusion injury in mice. Exp Cell Res 371:301-310 (2018). PubMed: 30098335
- Albrecht LV et al. Arginine methylation is required for canonical Wnt signaling and endolysosomal trafficking. Proc Natl Acad Sci U S A 115:E5317-E5325 (2018). PubMed: 29773710